
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is well-positioned for future growth, driven by its strong financial position, expanding product offerings, and successful partnerships with pharmaceutical companies. With Medicare coverage for their breast cancer tests and ongoing studies showing positive results, the company has potential for increased revenue through biopharmaceutical services and clinical diagnostics. Additionally, their focus on personalized cancer vaccines has attracted a large investment from Merck and has the potential for FDA approval in the future.
Bears say
Personalis is facing potential risks and challenges in its oncology-focused business, including competition from other genomic sequencing companies and uncertainties in reimbursement and pricing. Despite reporting successful clinical trial results for its products, the company may struggle to achieve profitability in the short-term due to limited reimbursement coverage and the need for further investments in research and development. Additionally, the company's financials may also be impacted by fluctuations in its stock price as it continues to use its ATM to raise cash, potentially diluting shareholder value.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares